Jean-Philippe Rocher
Nessuna posizione attualmente
Patrimonio netto: 169 015 $ in data 30/04/2024
Provenienza dei contatti di primo grado di Jean-Philippe Rocher
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 18 | |
University of Lyon
4
| College/University | Other Consumer Services | 4 |
GlaxoSmithKline KK
 GlaxoSmithKline KK Household/Personal CareConsumer Non-Durables GlaxoSmithKline KK researches, develops, imports, manufactures and sells toiletry products. The company was founded on August 18, 1928 and is headquartered in Tokyo, Japan
1
| Subsidiary | Household/Personal Care | 1 |
deVGen NV
 deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium.
1
| Subsidiary | Biotechnology | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Jean-Philippe Rocher tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chairman | |
Merck Serono SA
 Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| University of London | College/University | Doctorate Degree Doctorate Degree | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| OREXO AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ACTELION | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| NEKTAR THERAPEUTICS | Pharmaceuticals: Major | Chairman Chief Operating Officer | |
| University of Cambridge | College/University | Doctorate Degree Corporate Officer/Principal | |
| OBSEVA SA | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer | |
| Merck Sharp & Dohme Research Laboratories | Corporate Officer/Principal | ||
| KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Director/Board Member | |
| Medicines & Healthcare Products Regulatory Agency | General Government | Director/Board Member | |
Academy of Medical Sciences
 Academy of Medical Sciences Miscellaneous Commercial ServicesCommercial Services The Academy of Medical Sciences was founded in 1998 and provides biomedical and health research services. The non-profit company is based in London, UK. | Miscellaneous Commercial Services | Director/Board Member | |
AQIX Ltd.
 AQIX Ltd. Pharmaceuticals: MajorHealth Technology Aqix Ltd is proud of the affiliations formed with many of its customers and trading partners in an endeavor to bring this unique fluid technology to the biomedical industry on a global scale. Recent events have highlighted the emergence of the company's fluid technology in applications involving stem cell therapy, organ transplant technology, human tissue storage and transportation and preclinical drug bioassay. | Pharmaceuticals: Major | Chairman | |
| Ministerial Industry Strategy Group | Corporate Officer/Principal | ||
Merck Sharp & Dohme Corp.
 Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. | Pharmaceuticals: Major | Director/Board Member | |
| Georgetown University | College/University | Undergraduate Degree | |
British Pharmacological Society
 British Pharmacological Society Investment Trusts/Mutual FundsMiscellaneous The British Pharmacological Society is a charity and membership organization that aims to promote and advance the field of pharmacology. The private company is based in London, UK. The British company leads the way in researching and applying pharmacology worldwide. The company was founded in 1931. Rachel Lambert-Forsyth has been the CEO of the company since 2020. | Investment Trusts/Mutual Funds | Chairman | |
Covagen AG
 Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Biotechnology | Director/Board Member | |
EcoR1 Capital, LLC
 EcoR1 Capital, LLC Investment ManagersFinance EcoR1 Capital LLC (EcoR1) is an independent registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded by Oleg Nodelman in 2012. EcoR1 serves as the general partner of and investment adviser to investment funds and provides investment advice to separate account clients. | Investment Managers | Chief Executive Officer | |
| PROTHENA CORPORATION PLC | Biotechnology | Director/Board Member | |
Scorpion Therapeutics, Inc.
 Scorpion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
Paratus Sciences Corp.
 Paratus Sciences Corp. BiotechnologyHealth Technology Paratus Sciences Corp. is an American company that focuses on unlocking the secrets of bat biology. The company's main goal is to elucidate novel insights and identify new therapeutic targets. The company was founded by Thomas Zwaka, Richard Young, Paul Matsudaira. The CEO is Amir H. Nashat. | Biotechnology | Director/Board Member | |
| EcoR1 Panacea Holdings LLC | Chief Executive Officer | ||
ReCode Therapeutics, Inc.
 ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Pharmaceuticals: Major | Director/Board Member | |
| United Kingdom Department of Health & Social Care | General Government | Founder | |
| NUVATION BIO INC. | Biotechnology | Director/Board Member | |
| PANACEA ACQUISITION CORP. II | Financial Conglomerates | Chief Executive Officer | |
BVF Partners LP
 BVF Partners LP Investment ManagersFinance BVF Partners LP (BVF) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded in 1993 and is a subsidiary of BVF, Inc. BVF provides discretionary advisory services to private investment vehicles which includes commingled limited partnerships (the BVF Funds) and a limited liability entity organized for a single investor (Single Investor Fund) as well as to separately managed accounts. | Investment Managers | Corporate Officer/Principal | |
Biotechnology Value Fund LP
 Biotechnology Value Fund LP Investment ManagersFinance Part of BVF, Inc., Biotechnology Value Fund LP is an Alternative Investment Manager. The company is based in San Francisco, CA. | Investment Managers | Corporate Officer/Principal | |
| ANAPTYSBIO, INC. | Biotechnology | Director/Board Member | |
Aktis Oncology, Inc.
 Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | Medical/Nursing Services | Director/Board Member | |
| Pharmaceutical Industry Competitiveness Task Force | General Government | Founder | |
| FEINTOOL INTERNATIONAL HOLDING AG | Metal Fabrication | Chief Executive Officer | |
| UK Clinical Research Collaboration | Founder | ||
| Healthcare & Humanity Foundation | Founder | ||
| Weill Cornell Medical College | College/University | Doctorate Degree | |
Resurge International
 Resurge International Medical/Nursing ServicesHealth Services Resurge International operates surgical care facilities for poor children and adults. | Medical/Nursing Services | Director/Board Member | |
| CYTOMX THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman | |
Synchronicity Pharma, Inc.
 Synchronicity Pharma, Inc. Pharmaceuticals: OtherHealth Technology Synchronicity Pharma, Inc. discovers, develops and commercializes novel therapeutics. Its products identify components of the circadian system that can be targeted to treat metabolic and related disorders, such as diabetes, obesity, and cardiovascular diseases. The company was founded by Ross S. Bersot, Joseph S. Takahashi, Masashi Yanagisawas and Ron Evans in 2008 and is headquartered in San Jose, CA. | Pharmaceuticals: Other | Director/Board Member | |
| 4D MOLECULAR THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Quintessa Investment Co. Ltd.
 Quintessa Investment Co. Ltd. Investment ManagersFinance Quintessa Investment acts as alternative investment manager. It is engaged in financial investment activities. The company was founded on January 13, 2011 and is headquartered in Seoul, South Korea. | Investment Managers | Private Equity Investor | |
pH Pharma Co., Ltd.
 pH Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology pH Pharma Co. Ltd. engages in the developing and manufacturing of bio-pharmaceuticals. Its products include php-303, php-201, ab-101, nuvesse, alpine and torpedo products. The company was founded by Ho Young Huh on September 22, 2015 and is headquartered in Seoul, South Korea. | Pharmaceuticals: Major | Chief Executive Officer | |
| EIDOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 28 |
| Regno Unito | 12 |
| Svizzera | 7 |
| Svezia | 3 |
| Corea del Sud | 3 |
Settori
| Health Technology | 26 |
| Finance | 9 |
| Consumer Services | 5 |
| Government | 4 |
| Health Services | 3 |
Posizioni
| Director/Board Member | 152 |
| Corporate Officer/Principal | 68 |
| Chairman | 34 |
| Independent Dir/Board Member | 30 |
| Chief Executive Officer | 19 |
Contatti più connessi
| Insiders | |
|---|---|
| Antoine Papiernik | 48 |
| Ho Young Huh | 32 |
| Bharatt Chowrira | 24 |
| Didier Hoch | 24 |
| Beat E. Lüthi | 23 |
| Graham Dixon | 18 |
| Ray Hill | 18 |
| Oleg Nodelman | 15 |
| Alexandra Goll | 14 |
| Vincent Lawton | 11 |
| Werner Henrich | 10 |
| Michel Jacquet | 8 |
| Ben T. G. Tan | 8 |
| Fabrice Romano | 7 |
| Sonia Maria Poli | 7 |
- Borsa valori
- Insiders
- Jean-Philippe Rocher
- Connessioni Società
